Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on March 2, 2016. The report details the closing of a registered direct offering of common stock and warrants. Note: The request metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics
- Gross Proceeds: Approximately $5.0 million.
- Shares Issued: 15,625,000 shares of common stock.
- Warrants Issued: Warrants to purchase 11,718,750 shares of common stock.
- Warrant Exercise Price: $0.42 per share.
- Unit Structure: One share of common stock plus a warrant to purchase 0.75 of a share.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics beyond the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders resulting from the issuance of 15,625,000 new shares and associated warrants. This event was previously disclosed in a Form 8-K filed on February 26, 2016.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors related to the company's operations. It strictly reports the completion of the capital raise and the filing of a legal opinion regarding the legality of the issuance.
Investor Verification Checklist
- Verify the exact use of the $5.0 million in gross proceeds (not specified in this text).
- Confirm the total number of outstanding shares post-offering to assess dilution impact.
- Review the full warrant agreement terms, including expiration dates and exercise conditions.
- Check the February 26, 2016 Form 8-K for the initial terms and pricing details of the offering.